1. Academic Validation
  2. Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses

Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses

  • Nat Commun. 2025 Jul 1;16(1):5831. doi: 10.1038/s41467-025-60232-3.
Arne Matthys 1 2 Jan Felix 2 3 Joao Paulo Portela Catani 1 2 Kenny Roose 1 2 Wim Nerinckx 1 2 Benthe Van Buyten 1 2 Daria Fijalkowska 1 2 Nico Callewaert 1 2 Savvas N Savvides 2 3 Xavier Saelens 4 5
Affiliations

Affiliations

  • 1 VIB Center for Medical Biotechnology, VIB, Ghent, Belgium.
  • 2 Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
  • 3 Unit for Structural Biology, VIB-UGent Center for Inflammation Research, Ghent, Belgium.
  • 4 VIB Center for Medical Biotechnology, VIB, Ghent, Belgium. xavier.saelens@vib-ugent.be.
  • 5 Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium. xavier.saelens@vib-ugent.be.
Abstract

Influenza B viruses are antigenically diverse and contribute significantly to the annual influenza burden. Here we report influenza B virus neutralizing single-domain antibodies that target highly conserved regions of the hemagglutinin and neuraminidase. Structural studies by single particle electron cryo-microscopy (cryo-EM) revealed that one of these single-domain antibodies prevents the conformational transition of the viral hemagglutinin to the post-fusion state by targeting a quaternary epitope spanning two protomers in the hemagglutinin-stem region. A second single-domain antibody broadly inhibits influenza B neuraminidase activity, including an oseltamivir-resistant neuraminidase, and its complex with neuraminidase elucidated by single particle cryo-EM established that it binds to residues in the neuraminidase catalytic site. Head-to-tail fusions of these single-domain antibodies led to bispecific Binders that further improved the neutralization breadth and potency against influenza B viruses. These single-domain antibodies, fused to a human IgG1-Fc domain, fully protected female mice against an otherwise lethal influenza B virus challenge. Our findings underscore the potential of engineered single-domain antibodies to help control influenza B virus infections.

Figures
Products